Medicines Co scores FDA OK for new antibiotic, now up on the auction block
The Medicines Company’s infectious disease business just got more valuable.
The FDA has come through with an accelerated approval of Vabomere — the combo of vaborbactam, a new beta-lactamase inhibitor, and meropenem, the leading carbapenem — which should help its deals team as the company hunts up a buyer for all or part of that business group.
Technically, the OK went to Rempex, which The Medicines Company bought in 2013 for up to $474 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.